Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a

Journal of Lipid Research

Volumn 49, Issue 5, 2008, Pages 929-938

  Mukherjee, Purna ^a   Faber, Anthony C ^a   Shelton, Laura M ^a   Baek, Rena C ^a   Chiles, Thomas C ^a   Seyfried, Thomas N ^a  

^a BOSTON COLLEGE   (United States)

Author keywords

Glycosphingolipid; Growth factor receptor; Human umbilical endothelial cell migration; Matrigel plug assay; Phosphorylated akt

Indexed keywords

GANGLIOSIDE GD 1A; GANGLIOSIDE GM3; GROWTH FACTOR; MIGLUSTAT; PROTEIN KINASE B; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; DRUG DERIVATIVE; GANGLIOSIDE GD1ALPHA; GANGLIOSIDE GM1; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; BIOSYNTHESIS; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BRAIN; CATTLE; CELL CULTURE; CELL DIVISION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; MOUSE MUTANT; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; BRAIN; CATTLE; CELL DIVISION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; G(M1) GANGLIOSIDE; G(M3) GANGLIOSIDE; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; NEOVASCULARIZATION, PHYSIOLOGIC; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 50049110689     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R800006-JLR200     Document Type: Conference Paper

References (57)

1. Alessandri, G., S. Filippeschi, P. Sinibaldi, F. Mornet, P. Passera, F. Spreafico, P. M. Cappa, and P. M. Gullino. 1987. Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res. 47: 4243-4247.
2. Bai, H., and T. N. Seyfried. 1997. Influence of ganglioside GM3 and high density lipoprotein (HDL) on the cohesion of mouse brain tumor cells. J. Lipid Res. 38: 160-172.
3. Hakomori, S. 1996. Tumor malignancy defined by aberrant glycosylation and sphingo (glyco) lipid metabolism. Cancer Ries. 56: 5309-5318.
4. Zeng, G., L. Gao, S. Birkle, and R. K. Yu. 2000. Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production. Cancer Res. 60: 6670-6676.
5. Alessandri, G., P. Cornaglia Ferraris, and P. M. Gullino. 1997. Angiogenic and angiostatic microenvironment in tumors-role of gangliosides. Acta Oncol. 36: 383-387.
6. Alessandri, G., G. De Cristan, M. Ziche, A. P. Cappa, and P. M. Gullino. 1992. Growth and motility of microvascular endothelium are modulated by the relative concentration of gangliosides in the medium. J. Cell. Physiol. 151: 23-28.
7. Valentino, L. A., and S. Ladisch. 1992. Localization of shed human tumor gangliosides: association with serum lipoproteins. Cancer Res. 52: 810-814.
8. Abate, L. E., P. Mukherjee, and T. N. Seyfried. 2006. Gene-linked shift in ganglioside distribution influences growth and vascularity in a mouse astrocytoma. J. Neurochem. 98: 1973-1984.
9. Olshefski, R., and S. Ladisch. 1996. Intercellular transfer of shed tumor cell gangliosides. FEBS Lett. 386: 11-14.
10. Ladisch, S., B. Gillard, C. Wong, and L. Ulsh. 1983. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res. 43: 3808-3813.
11. Ladisch, S., S. Kitada, and E. F. Hays. 1987. Gangliosides shed by tumor cells enhance tumor formation in mice. J. Clin. Invest. 79:1879-1882.
12. Manfredi, M. G., S. Lim, K. P. Claffey, and T. N. Seyfried. 1999. Gangliosides influence angiogenesis in an experimental mouse brain tumor. Cancer Res. 59: 5392-5397.
13. Liu, Y.,J. McCarthy, and S. Ladisch. 2006. Membrane ganglioside enrichment lowers the threshold for vascular endothelial cell angiogenic signaling. Cancer Res. 66: 10408-10414.
14. Mitsuzuka, K., K. Handa, M. Satoh, Y. Arai, and S. Hakomori. 2005. A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3- mediated interaction of alpha3beta1 integrin with CD9. J. Biol. Chem. 280: 35545-35553.
15. Fujimoto, Y., S. Izumoto, T. Suzuki, M. Kinoshita, N. Kagawa, K. Wada, N. Hashimoto, M. Maruno, Y. Nakatsuji, and T. Yoshimine. 2005. Ganglioside GM3 inhibits proliferation and invasion of glioma. J. Neurooncol. 71: 99-106.
16. Bassi, R., P. Viani, P. Giussani, L. Riboni, and G. Tettamanti. 2001. GM3 ganglioside inhibits endothelin-1-mediated signal transduction in C6 glioma cells. FEBS Lett. 507: 101-104.
17. Noll, E. N., J. Lin, Y. Nakatsuji, R. H. Miller, and P. M. Black. 2001. GM3 as a novel growth regulator for human gliomas. Exp. Neurol. 168: 300-309.
18. De Cristan, G., L. Morbidelli, G. Alessandri, M. Ziche, A. P. Cappa, and P. M. Gullino. 1990. Synergism between gangliosides and basic fibroblastic growth factor in favouring survival, growth, and motility of capillary endothelium. J. Cell. Physiol. 144: 505-510.
19. Ravindranath, M. H., T. Tsuchida, D. L. Morton, and R. F. Irie. 1991. Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer. 67: 3029-3035.
20. Shochat, S. J., N. L. Corbelletta, M. A. Repman, and C. L. Schengrund. 1987. A biochemical analysis of thoracic neuroblasto- mas: a Pediatric Oncology Group study. J. Pediatr. Surg. 22: 660-664.
21. Chu, S. H., Y. B. Ma, H. Zhang, D. F. Feng, Z. A. Zhu, Z. Q. Li, and X. H. Yuan. 2007. Hepatocyte growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells. J. Neurooncol. 85: 33-38.
22. Koochekpour, S., A. Merzak, and G. J. Pilkington. 1996. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro. Cancer Lett. 102: 209-215.
23. Ranes, M. K., M. El-Abbadi, M. G. Manfredi, P. Mukherjee, F. M. Platt, and T. N. Seyfried. 2001. N-Butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours. Br. J. Cancer. 84: 1107-1114.
24. Weiss, M., S. Hettmer, P. Smith, and S. Ladisch. 2003. Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase. Cancer Res. 63: 3654-3658.
25. Deng, W., R. Li, and S. Ladisch. 2000. Influence of cellular ganglioside depletion on tumor formation. J. Natl. Cancer Inst. 92: 912-917.
26. Folkman, J. 1992. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3: 65-71.
27. Claffey, K. P., K. Abrams, S. C. Shih, L. F. Brown, A. Mullen, and M. Keough. 2001. Fibroblast growth factor 2 activation of stromal cell vascular endothelial growth factor expression and angiogenesis. Lab. Invest. 81: 61-75.
28. Ferrara, N., and T. Davis Smyth. 1997. The biology of vascular endothelial growth factor. Endocr. Rev. 18: 4-25.
29. Lang, Z., M. Guerrera, R. Li, and S. Ladisch. 2001. Ganglioside GD1a enhances VEGF-induced endothelial cell proliferation and migration. Biochem. Biophys. Res. Commun. 282: 1031-1037.
30. Ziche, M., G. Alessandri, and P. M. Gullino. 1989. Gangliosides promote the angiogenic response. Lab. Invest. 61: 629-634.
31. Ziche, M., L. Morbidelli, G. Alessandri, and P. M. Gullino. 1992. Angiogenesis can be stimulated or repressed in vivo by a change in GM3:GD3 ganglioside ratio. Lab. Invest. 67: 711-715.
32. Wang, X. Q., P. Sun, and A. S. Paller. 2003. Ganglioside GM3 blocks the activation of epidermal growth factor receptor induced by integrin at specific tyrosine sites. J. Biol. Chem. 278: 48770-48778.
33. Bremer, E. G., J. Schlessinger, and S. Hakomori. 1986. Ganglioside-mediated modulation of cell growth. J. Biol. Chem. 261: 2434-2440.
34. Yoon, S. J., K. Nakayama, T. Hikita, K. Handa, and S. I. Hakomori. 2006. Epidermal growth factor receptor tyrosine kinase is modulated by GM3 interaction with N-linked GlcNAc termini of the receptor. Proc. Natl. Acad. Sci. USA. 103: 18987-18991.
35. Veikkola, T., M. Karkkainen, L. Claesson-Welsh, and K. Alitalo. 2000. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60: 203-212.
36. Gille, H., J. Kowalski, B. Li, J. LeCouter, B. Moffat, T. F. Zioncheck, N. Pelletier, and N. Ferrara. 2001. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 276: 3222-3230.
37. Mukherjee, P., M. M. El-Abbadi, J. L. Kasperzyk, M. K Ranes, and T. N. Seyfried. 2002. Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br. J. Cancer. 86: 1615-1621.
38. Wakasugi, K., B. M. Slike, J. Hood, A. Otani, K.L. Ewalt, M. Friedlander, D. A. Cheresh, and P. Schimmel. 2002. A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc. Natl. Acad. Sci. USA. 99: 173-177.
39. Seyfried, T. N., A. M. Novikov, R. A. Irvine, and J. V. Brigande. 1994. Ganglioside biosynthesis in mouse embryos: sialyltransferase IV and the asialo pathway. J. Lipid Ries. 35: 993-1001.
40. Muthing, J., S. Duvar, D. Heitmann, F. G. Hanisch, U. Neumann, G. Lochnit, R. Geyer, and J. Peter-Katalinic. 1999. Isolation and structural characterization of glycosphingolipids of in vitro propagated human umbilical vein endothelial cells. Glycobiology. 9: 459-468.
41. Gullino, P. M., M. Ziche, and G. Alessandri. 1990. Gangliosides, copper ions and angiogenic capacity of adult tissues. Cancer Metastasis Rev. 9: 239-251.
42. Liu, Y., R. Li, and S. Ladisch. 2004. Exogenous ganglioside GD1a enhances epidermal growth factor receptor binding and dimerization. J. Biol. Chem. 279: 36481-36489.
43. Slevin, M., S. Kumar, X. He, and J. Gaffney. 1999. Physiological concentrations of gangliosides GM1, GM2 and GM3 differentially modify basic-fibroblast-growth-factor-induced mitogenesis and the associated signalling pathway in endothelial cells. Int. J. Cancer. 82:412-423.
44. Lauc, G., and M. Heffer-Lauc. 2006. Shedding and uptake of gangliosides and glycosylphosphatidylinositol-anchored proteins. Biochim. Biophys. Acta. 1760: 584-602.
45. Ferrara, N., H. P. Gerber, and J. LeCouter. 2003. The biology of VEGF and its receptors. Nat. Med. 9: 669-676.
46. Cho, C. H., C. S. Lee, M. Chang, I. H. Jang, S. J. Kim, I. Hwang, S. H. Ryu, C. O. Lee, and G. Y. Koh. 2004. Localization of VEGFR-2 and PLD2 in endothelial caveolae is involved in VEGF-induced phosphorylation of MEK and ERK. Am. J. Physiol. Heart Circ. Physiol. 286: H1881-H1888.
47. Li, R., J. Manela, Y. Kong, and S. Ladisch. 2000. Cellular gangliosides promote growth factor-induced proliferation of fibro-blasts. J. Biol. Chem. 275: 34213-34223.
48. Hakomori, S. I. 2002. Inaugural article. The glycosynapse. Proc. Natl. Acad. Sci. USA. 99: 225-232.
49. Mineo, C., G. L. James, E. J. Smart, and R. G. Anderson. 1996. Localization of epidermal growth factor-stimulated Ras/Raf-1 interaction to caveolae membrane. J. Biol. Chem. 271: 11930-11935.
50. Kaji, T., C. Yamamoto, M. Oh-i, Y. Fujiwara, Y. Yamazaki, T. Morita, A. H. Plaas, and T. N. Wight. 2006. The vascular endothelial growth factor VEGF165 induces perlecan synthesis via VEGF receptor-2 in cultured human brain microvascular endothelial cells. Biochim. Biophys. Acta. 1760: 1465-1474.
51. Shintani, Y., S. Takashima, Y. Asano, H. Kato, Y. Liao, S. Yamazaki, O. Tsukamoto, O. Seguchi, H. Yamamoto, T. Fukushima, et al. 2006. Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling. EMBO J. 25: 3045-3055.
52. Kanda, T., T. Ariga, M. Yamawaki, H. Yoshino, X. B. Gu, and R. K. Yu. 1997. Glycosyltransferase activities in cultured endothelial cells of bovine brain microvascular origin. Neurochem. Res. 22:463-466.
53. Tatewaki, K., T. Yamaki, Y. Maeda, H. Tobioka, H. Piao, H. Yu, Y. Ibayashi, N. Sawada, and K. Hashi. 1997. Cell density regulates crypticity ofGM3 ganglioside on human glioma cells. Exp. Cell Res. 233: 145-154.
54. Toledo, M. S., E. Suzuki, K. Handa, and S. Hakomori. 2005. Effect of ganglioside and tetraspanins in microdomains on interaction of integrins with fibroblast growth factor receptor. J. Biol. Chem. 280:16227-16234.
55. Gu, J., A. Fujibayashi, K. M. Yamada, and K. Sekiguchi. 2002. Laminin-10/11 and fibronectin differentially prevent apoptosis induced by serum removal via phosphatidylinositol 3-kinase/Akt- and MEK1/ERK-dependent pathways. J. Biol. Chem. 277: 19922-19928.
56. Choi, H. J., T. W. Chung, S. K. Kang, Y. C. Lee, J. H. Ko, J. G. Kim, and C. H. Kim. 2006. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression-transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway. Glycobiology. 16: 573-583.
57. Castellino, R. C., and D. L. Durden. 2007. Mechanisms ofdisease: the PI3K-Akt-PTEN signaling node-an intercept point for the control of angiogenesis in brain tumors. Nat. Clin. Pract. 3: 682-693.